Physicians and researchers present groundbreaking findings from late-breaking clinical trials, follow-up data from major randomized trials and registries, and first-in-man experiences with novel devices or drugs. Each presentation is followed by a discussion and Q&A with a panel of expert faculty.
Important 2024 Dates
VIVA and The VEINS embargo Late-Breaking Clinical Trial information from becoming public until after the commencement of the session as listed in the conference program or on viva-foundation.org. No publication, exhibitor, or affiliated company may disseminate information until after the commencement of the Late-Breaking Clinical Trial session in which it is presented.
Research must be original and may not have been presented prior to presentation at VIVA or The VEINS 2024. Abstract submissions should address areas of endovascular medicine/intervention and can report the results of basic science investigations as well as clinical or pre-clinical studies.
Abstract submissions must include:
The total abstract length may not exceed 2,500 characters, exclusive of title or figures.
The following information must be provided upon submission:
Abstracts will be evaluated and scored based on the following criteria:
Accepted late-breaking clinical trials will be presented:
The review committee may determine that your abstract may be more appropriate for a different session or conference than you originally submitted.
If you have questions please contact Brita Thorne via e-mail: abstracts@viva-foundation.org
